Patient P-01433
Therapy response
Stable
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Unstable
Discontinuation risk
76%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 57 GI-04 recommended — GI Support Protocol GI-04
- Day 58 Patient accepted — Started GI-04 in the companion
- Day 65 ME-01 recommended — Monitoring Escalation ME-01
- Day 66 GI symptom burden −29% vs expected — GI Support Protocol GI-04
- Day 66 Patient accepted — Started ME-01 in the companion
- Day 69 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 72 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- Inflammatory activity+8
- GI instability+6
- Toxicity+3
What helped?
- GI Support Protocol GI-04Day 57Result: symptom burden −29%
- Monitoring Escalation ME-01Day 65Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
61%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 55
- WearableHRV 36 ms, trending down
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 51
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 54 and rising
- Autonomic recovery ↓45
- WearableResting HR 77 bpm
- Wearable3,387 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 1.8 · butyrate capacity 38/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 40 ms
- Sleep
- 7.3 h
- Steps
- 1,933
- Resting HR
- 77 bpm
Daily log: GI score 54, nutritional resilience 39, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 22% | S19 | AD-05 | improved | 61 |
| P-01377 | 21% | S11 | AD-05 | no change | 42 |
| P-01708 | 36% | S07 | CR-01 | improved | 59 |
| P-01696 | 33% | S20 | CR-01 | improved | 59 |
| P-01371 | 32% | S06 | CR-01 | improved | 63 |
| P-01835 | 32% | S17 | CR-01 | improved | 56 |
| P-01388 | 31% | S17 | CR-01 | improved | 59 |
| P-01877 | 31% | S01 | CR-01 | improved | 67 |
| P-01442 | 30% | S13 | CR-01 | improved | 61 |
| P-01430 | 22% | S05 | CR-01 | improved | 54 |
| P-01342 | 21% | S11 | DT-01 | improved | 48 |
| P-01393 | 54% | S14 | GI-04 | improved | 53 |